Proteasome inhibitor bortezomib targeted tumor-endothelial cell interaction in T-cell leukemia/lymphoma

Annals of Hematology

Volumn 90, Issue 1, 2011, Pages 53-58

  Shi, Wen Yu ^a,b   Wang, Li ^a,b   Xiao, Dan ^a,b   Yao, Yin ^a   Yang, Fan ^a,b   Jiang, Xiao Xing ^a,b   Leboeuf, Christophe ^b,c   Janin, Anne ^b,c   Chen, Sai Juan ^a,b   Zhao, Wei Li ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Pole de Recherches Franco Chinois en Science du Vivant et Genomique   (China)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Bortezomib; Endothelial cell; Intracellular cell adhesion molecule 1; T cell leukemia; T cell lymphoma

Indexed keywords

BORTEZOMIB; INTERCELLULAR ADHESION MOLECULE 1; PROTEASOME INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CELL ADHESION; CELL CONTACT; CELL GROWTH; CELL INFILTRATION; CELL INTERACTION; CELL MIGRATION; CELL PROLIFERATION; CELL ULTRASTRUCTURE; COCULTURE; CONTROLLED STUDY; CULTURE TECHNIQUE; CYTOTOXICITY; DOWN REGULATION; DRUG MECHANISM; DRUG TARGETING; ENDOTHELIUM CELL; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL LINE; LYMPHOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T CELL LEUKEMIA; T CELL LYMPHOMA; TUMOR CELL; TUMOR NECROSIS; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CELL COMMUNICATION; CELL MOVEMENT; ENDOTHELIAL CELLS; ENZYME INHIBITORS; HUMANS; JURKAT CELLS; LEUKEMIA, T-CELL; LYMPHOMA, T-CELL; MICE; MICE, NUDE; MOLECULAR TARGETED THERAPY; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78651323529     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-010-1022-1     Document Type: Article

References (19)

1. D Hoelzer N Gokbuget O Ottmann CH Pui MV Relling FR Appelbaum JJ van Dongen T Szczepanski 2002 Acute lymphoblastic leukemia Hematology (Am Soc Hematol Educ Program ) 2002 162 192
2. KJ Savage 2005 Aggressive peripheral t-cell lymphomas (specified and unspecified types) Hematology (Am Soc Hematol Educ Program) 2005 267 277
3. W Mai H Meng J Jin L Wang 2006 Treatment with bortezomib in a patient with heavily pretreated refractory T-cell lymphoblastic lymphoma Eur J Haematol 77 445 447 10.1111/j.0902-4441.2006.t01-1-EJH2889.x 16930138 (Pubitemid 44483950)
4. P Bonvini E Zorzi G Basso A Rosolen 2007 Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in cd-30+ anaplastic large cell lymphoma Leukemia 21 838 842 1:CAS:528: DC%2BD2sXjt1WktL8%3D 17268529
5. J Lee C Suh HJ Kang BY Ryoo J Huh YH Ko HS Eom K Kim K Park WS Kim 2008 Phase I study of proteasome inhibitor bortezomib plus chop in patients with advanced, aggressive T-cell or NK/T-cell lymphoma Ann Oncol 19 2079 2083 1:STN:280:DC%2BD1cjlsFGiug%3D%3D 10.1093/annonc/mdn431 18689866
6. PL Zinzani G Musuraca M Tani V Stefoni E Marchi M Fina C Pellegrini L Alinari E Derenzini A de Vivo E Sabattini S Pileri M Baccarani 2007 Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma J Clin Oncol 25 4293 4297 1:CAS:528: DC%2BD2sXhtFyis7jI 10.1200/JCO.2007.11.4207 17709797 (Pubitemid 47548570)
7. JB Sunwoo Z Chen G Dong N Yeh C Crowl Bancroft E Sausville J Adams P Elliott C Van Waes 2001 Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma Clin Cancer Res 7 1419 1428 1:CAS:528: DC%2BD3MXktlels7k%3D 11350913
8. WL Zhao YY Liu QL Zhang L Wang C Leboeuf YW Zhang J Ma JF Garcia YP Song JM Li ZX Shen Z Chen A Janin SJ Chen 2008 PRDM1 is involved in chemoresistance of T-cell lymphoma and down-regulated by the proteasome inhibitor Blood 111 3867 3871 1:CAS:528:DC%2BD1cXktlWmtL4%3D 10.1182/blood-2007-08-108654 18235046
9. QL Zhang L Wang YW Zhang XX Jiang F Yang WL Wu A Janin Z Chen ZX Shen SJ Chen WL Zhao 2009 The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis Leukemia 23 1507 1514 1:CAS:528: DC%2BD1MXpvF2kurk%3D 10.1038/leu.2009.41 19282831
10. GL Semenza 2003 Angiogenesis in ischemic and neoplastic disorders Annu Rev Med 54 17 28 1:CAS:528:DC%2BD3sXit1ejs7o%3D 10.1146/annurev.med.54.101601. 152418 12359828 (Pubitemid 37386383)
11. T Hideshima D Chauhan R Schlossman P Richardson KC Anderson 2001 The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications Oncogene 20 4519 4527 1:CAS:528: DC%2BD3MXlvVGktr4%3D 10.1038/sj.onc.1204623 11494147 (Pubitemid 32772434)
12. JR Kanwar RW Berg Y Yang RK Kanwar LM Ching X Sun GW Krissansen 2003 Requirements for ICAM-1 immunogene therapy of lymphoma Cancer Gene Ther 10 468 476 1:CAS:528:DC%2BD3sXjvF2lu74%3D 10.1038/sj.cgt.7700590 12768192 (Pubitemid 36667133)
13. SD Belanger Y St-Pierre 2005 Role of selectins in the triggering, growth, and dissemination of T-lymphoma cells: Implication of L-selectin in the growth of thymic lymphoma Blood 105 4800 4806 1:CAS:528:DC%2BD2MXlsVWisr0%3D 10.1182/blood-2004-04-1406 15705798 (Pubitemid 40807306)
14. PR Clark TD Manes JS Pober MS Kluger 2007 Increased ICAM-1 expression causes endothelial cell leakiness, cytoskeletal reorganization and junctional alterations J Invest Dermatol 127 762 774 1:CAS:528:DC%2BD2sXivVGlsbw%3D 10.1038/sj.jid.5700670 17195014 (Pubitemid 46434665)
15. VJ Palombella EM Conner JW Fuseler A Destree JM Davis FS Laroux RE Wolf J Huang S Brand PJ Elliott D Lazarus T McCormack L Parent R Stein J Adams MB Grisham 1998 Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis Proc Natl Acad Sci USA 95 15671 15676 1:CAS:528:DyaK1MXhvFeiug%3D%3D 10.1073/pnas.95.26.15671 9861028 (Pubitemid 29018758)
16. KS Ahn G Sethi TH Chao ST Neuteboom MM Chaturvedi MA Palladino A Younes BB Aggarwal 2007 Salinosporamide A (NPI-0052) potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through down-modulation of NF-kappaB regulated gene products Blood 110 2286 2295 1:CAS:528:DC%2BD2sXhtFCnsbzP 10.1182/blood-2007-04-084996 17609425 (Pubitemid 47523146)
17. K Noborio-Hatano J Kikuchi M Takatoku R Shimizu T Wada M Ueda M Nobuyoshi I Oh K Sato T Suzuki K Ozaki M Mori T Nagai K Muroi Y Kano Y Furukawa K Ozawa 2009 Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma Oncogene 28 231 242 1:STN:280:DC%2BD1M%2Fntleisw%3D%3D 10.1038/onc.2008.385 18850009
18. DJ McConkey K Zhu 2008 Mechanisms of proteasome inhibitor action and resistance in cancer Drug Resist Updat 11 164 179 1:CAS:528:DC%2BD1cXhtF2ku7fJ 10.1016/j.drup.2008.08.002 18818117
19. T Hideshima D Chauhan Y Shima N Raje FE Davies YT Tai SP Treon B Lin RL Schlossman P Richardson G Muller DI Stirling KC Anderson 2000 Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy Blood 96 2943 2950 1:CAS:528:DC%2BD3cXnslGnsbw%3D 11049970